MannKind (MNKD) Stock Forecast & Price Target

MannKind is supported by a strengthening commercial base, with 3Q revenues of $101.9MM, Tyvaso DPI royalties of $37.5MM, and FUROSCIX/ReadyFlow showing rapid uptake as ~90% of new prescriptions quickly shifted to the autoinjector, suggesting the revenue miss was largely transitional rather than structural. Afrezza is also improving, as pediatric prescriptions rose to 23% of 3Q TRx with >2,000 patients treated since launch and >600 prescribers, while the company expects Q4/26 profitability on both a GAAP and non-GAAP basis and annual profitability in 2027. Longer term, the outlook is reinforced by durable Tyvaso DPI demand, >$1B in estimated UTHR-related revenues 2027–2030, and a pipeline that includes MNKD-201 and ralinepag DPI, all of which could add meaningful upside without a stated need to raise capital.

MannKind is viewed negatively because its core revenue base remains heavily dependent on Tyvaso DPI, which contributed about $128M in 2025 and exposes the company to partner-controlled royalty risk as UTHR’s planned SMI treprostinil device could pressure the stream in 2027. Internally, profitability remains fragile: R&D was $14.4MM, SG&A jumped to $61.4MM, and adj. net income was a $3.6MM loss, while debt of about $422M against roughly $111M cash leaves limited flexibility if growth stalls. The outlook is also restrained by execution and development risk across Furoscix, early pediatric Afrezza adoption, and MNKD-201, whose efficacy is unproven and could meaningfully reduce modeled upside if it fails.